Galapagos to split into two companies, slash headcount as it eyes turnaround
Galapagos is looking for a fresh start after a rough few years. The Belgian biotech has outlined plans to branch off into two publicly traded businesses in a move that will see it terminate around ...
View ArticleVir’s early T cell engager data offer first look at cancer pivot, stock jumps
Interim data on two T cell engagers that Vir Biotechnology licensed from Sanofi last year have begun to justify the biotech’s strategic shift into oncology. But the data are very early, and ...
View ArticleExclusive: GV-backed Prudentia launches with $7M to boost pharma dealmaking
Ahead of the busiest week for biopharma dealmaking at the annual JP Morgan Healthcare Conference, a new startup launched, believing its software will help prevent drugmakers from missing out on their...
View ArticleNovo-allied Aspect Biosystems nabs $115M for bioprinted tissue therapies
A Canadian biotech creating bioprinted tissue therapeutics for Type 1 diabetes, obesity and other endocrine and metabolic disorders has raised $115 million in a Series B. Vancouver-based Aspect...
View ArticleARCH, F-Prime and Mubadala pump $200M into former Denali programs
A new startup has emerged with $200 million and access to multiple preclinical drug candidates from neuroscience drugmaker Denali Therapeutics. On Wednesday morning, South San Francisco-based Tenvie...
View ArticleRoche's Chugai partners with Swiss ADC biotech Araris
Chugai, a Japanese pharma owned by Roche, is partnering with a small Swiss biotech to work on next-generation antibody-drug conjugates that deliver multiple cytotoxic molecules. Chugai will pay an...
View ArticleSolid Bio's former CEO launches new rare disease startup with €65M Series A
A new startup aiming to tackle rare diseases de-stealthed Wednesday morning with a CEO experienced in the space. Alesta Therapeutics took the wraps off its €65 million Series A ($67 million) that it...
View ArticleSana’s stock soars on new cell therapy data; UniQure’s $75M offering
Plus, news about Bioinvent, Alpha Cognition, Neumirna Therapeutics and Cassava Sciences: Sana Biotechnology finds life with new type 1 diabetes cell therapy data: The once high-flying biotech saw its...
View ArticleResilience cuts 120 employees at a former bluebird gene therapy site
National Resilience is laying off 120 staffers from its gene therapy facility in North Carolina, only a month after the San Diego-headquartered CDMO shrunk its headcount in Florida. This latest round...
View ArticleGene editing startup Scribe Therapeutics cuts staff by 20%
Scribe Therapeutics, a biotech co-founded by CRISPR pioneer Jennifer Doudna, is reducing its workforce by about 20%, the company confirmed to Endpoints News. CEO Ben Oakes told Endpoints by phone...
View ArticleTranscarent buys health navigation incumbent Accolade for $621M
Unicorn startup Transcarent has bought up a publicly traded rival as it looks to expand as a health navigation giant in one of the first health tech deals of the year. Accolade shareholders will...
View ArticleAstellas stops developing autologous cell therapy for lymphoma
Astellas has ended work on a cell therapy that it was exploring for CD20-positive B cell lymphomas, the Japan-based pharma confirmed to Endpoints News on Wednesday. The pharma giant ended a
View ArticleAhead of adcomm, FDA discusses Seikagaku's mixed trial results for its lumbar...
Japan-based Seikagaku will face an FDA advisory committee on Friday, with the agency raising concerns ahead of the meeting regarding the efficacy of its condoliase injection for the treatment of...
View ArticlePfizer, GSK add risk of Guillain-Barré to RSV vaccine labels
Pfizer and GSK’s RSV vaccines have a new warning at the request of the FDA, relaying an increased risk of Guillain-Barré syndrome within the first 42 days post-vaccination. The agency said
View ArticleRevance weighs competing buyout offer amid push from original bidder
Revance Therapeutics said Wednesday it will have talks with Teoxane on its bid to take over Revance's company. But Crown Laboratories — the initial bidder — has made clear it won't wait much longer on...
View ArticleFirst-ever gene edit of infant boy leads to apparent cure
A baby boy born with a debilitating genetic disease will likely no longer require a liver transplant to stabilize his condition, thanks to a first-of-its-kind genetic medicine he got at 6 months of...
View ArticleMaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host...
French biotech MaaT Pharma says its acute graft-versus-host disease treatment exceeded expectations in a single-arm Phase 3 study in Europe. The company now intends to submit MaaT013 for regulatory...
View ArticleAiolos team reunites with $411M for new biotech with obesity drugs from China
There's a shopping bonanza for new obesity medicines going on among a marquee cohort of biopharma investors who are in-licensing treatment candidates from Chinese and European drug developers. Joining...
View ArticleH1 buys General Catalyst-backed Ribbon Health
H1 has bought Ribbon Health in one of the first health tech deals announced this year, the companies revealed Wednesday. The deal allows H1, an analytics company that connects doctors to organizations...
View ArticleCoave raises €32M Series A despite being two years away from the clinic
More than many other corporate VCs, Novo Holdings has the cash to take risks. Its most recent is co-leading the €32 million ($33 million) Series A financing of Coave Therapeutics, a gene therapy...
View Article